Qiagen N.V.
NYSE:QGENMedical - Diagnostics & Research
-$0.35 today
- Market cap
- $10.23B
- Beta
- 0.66
- P/E (TTM)
- 18.6
- EPS (TTM)
- $1.94
- Dividend yield
- 0.69%
Volume 4.26M
Average 2.07M
Returns on capital
Qiagen N.V. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.2%
avg 7.2%
ROIC
7.8%
avg 4.5%
ROA
6.7%
avg 3.9%
Analysis
ROE is currently the strongest return metric at 11.2% versus its period average of 7.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Thierry Bernard | Member of Management Board | USD 2.43M | 62 | — | — |
Roland Sackers | Chief Financial Officer, MD & Member of Management Board | USD 1.33M | 58 | — | — |
Thomas Theuringer | Senior Director & Head of External Communications | — | — | — | — |
John Gilardi | Vice President & Head of Corporate Communications | — | — | — | — |
Jonathan Pratt | CEO & Member of Management Board | — | 56 | — | — |
Nitin Sood | Senior VP & Head of Product Portfolio & Innovation | — | 53 | — | — |
Stephany Foster | Senior Vice President & Head of Human Resources | — | 47 | — | — |
Thomas Schweins | Senior Vice President of Life Science Business Area | — | — | — | — |
Antonio Santos | Senior Vice President & Head of Global Operations | — | — | — | — |
Daniel Wendorff CEFA CIIA | VP & Head of Investor Relations | — | — | — | — |
Jean-Pascal Viola | Senior Vice President & Head of Corporate Strategy and Business Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -0.2% | +10.1% (5yr)1 analysts |
| Revenue | N/A | N/A | -0.8% | +4.2% (5yr)6 analysts |
| Net Income | N/A | N/A | +0.1% | +10.0% (5yr)6 analysts |
| EBIT | N/A | N/A | -0.7% | +11.6% (5yr)6 analysts |
Analysis
Recent growth has been strongest in Net Income at +0.1% over three years. Forward estimates point to EBIT at +11.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Qiagen N.V. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about QGEN's management, answered from reported figures.
Who manages QGEN?
Qiagen N.V. (QGEN) lists 11 active executives. The top listed executive is Roland Sackers, Chief Financial Officer, MD & Member of Management Board.
Continue the stock analysis
Jump to another research area for this company.